What is the appropriate emergency management of pediatric anaphylaxis, including epinephrine dosing, positioning, adjunct medications, monitoring, and follow‑up care?

Pediatric Anaphylaxis: Emergency Management

Immediately administer intramuscular epinephrine 0.01 mg/kg (maximum 0.3 mg in prepubertal children, 0.5 mg in adolescents) into the mid-outer thigh as soon as anaphylaxis is recognized—this is the only life-saving intervention and delays are associated with fatal outcomes. 1, 2

Recognition

Anaphylaxis presents with sudden onset (minutes to hours) after allergen exposure, typically involving multiple organ systems 1:

• Skin/mucosa: Urticaria, angioedema, pruritus, flushing
• Respiratory: Stridor, wheeze, dyspnea, throat tightness, cough, cyanosis
• Cardiovascular: Tachycardia, hypotension, weak pulse, dizziness, syncope, incontinence
• Gastrointestinal: Persistent vomiting, crampy abdominal pain, diarrhea
• Neurologic: Behavioral changes (infants), altered mental status, sense of doom

Critical pitfall: Not all symptoms need to be present—even isolated respiratory or cardiovascular symptoms after allergen exposure warrant epinephrine 1.

Immediate Management Algorithm

1. First-Line Treatment: Epinephrine

Dosing 1, 2:

• Weight-based: 0.01 mg/kg IM
• Prepubertal children: Maximum 0.3 mg
• Adolescents: Maximum 0.5 mg
• Autoinjector dosing: 0.15 mg for young children, 0.3 mg for older children/teens

Administration 1:

• Route: Intramuscular into mid-outer thigh (vastus lateralis)—never buttocks, digits, hands, or feet 2
• Repeat every 5-15 minutes if inadequate response
• 6-19% of pediatric patients require a second dose; third doses are infrequent 1

2. Positioning 1

• Supine with legs elevated (default position)
• Allow sitting upright only if severe respiratory distress or vomiting
• Never allow standing, walking, or running—sudden position changes can precipitate cardiovascular collapse

3. Call for Help

• Community settings: 911/EMS immediately 1
• Healthcare settings: Activate resuscitation team 1

4. Refractory Anaphylaxis

For persistent symptoms after 2 IM epinephrine doses 3, 4:

• Continue IM epinephrine every 5 minutes
• Prepare IV epinephrine infusion (initiate after 3rd dose or earlier at provider discretion)
• Aggressive IV fluid resuscitation for shock
• Supplemental oxygen, airway management as needed
• Consider second-line vasopressors if needed

Adjunct Medications

Critical evidence gap: The 2020 practice parameter found very low certainty evidence for antihistamines and glucocorticoids 5.

Key findings 5:

• No clear evidence that antihistamines or glucocorticoids prevent biphasic reactions
• Glucocorticoids showed a nonsignificant inverse trend with biphasic reactions in adults but opposite association in children (possibly confounded by severity)
• One registry suggested antihistamines may provide benefit when used with epinephrine, but glucocorticoids with epinephrine resulted in worse outcomes

Bottom line: Antihistamines and corticosteroids are adjunctive only and must never delay or replace epinephrine 5, 4, 6.

Monitoring and Observation

• Keep all patients under observation in a setting capable of managing anaphylaxis until symptoms fully resolve 5
• Monitor for biphasic reactions (risk factors: greater severity, requiring >1 epinephrine dose) 5
• Transport to emergency department, preferably by EMS 1
• Additional interventions may include supplemental oxygen, IV fluids, bronchodilators for persistent bronchospasm despite epinephrine 6

Discharge and Follow-Up

All patients must receive 5:

1. Epinephrine autoinjector prescription with administration training
2. Written anaphylaxis emergency action plan 1
3. Education covering:
   • Trigger avoidance
   • Recognition of signs/symptoms
   • Biphasic anaphylaxis risk
   • When and how to use autoinjector
4. Referral to allergist for trigger identification and long-term management 5

Special consideration: In rare circumstances (resolved anaphylaxis with drug trigger and high likelihood of successful avoidance), autoinjector prescription may be deferred through shared decision-making 5.

Safety Considerations

• No absolute contraindication to epinephrine in anaphylaxis 2
• Transient pallor, tremor, anxiety, palpitations are expected pharmacologic effects, not true adverse reactions 1
• Serious adverse effects from IM epinephrine are rare in children 1
• Sulfite presence in epinephrine formulations should not deter use for anaphylaxis 2
• Infants may receive relatively higher doses with 0.15 mg autoinjectors (up to 2-fold for those ≤7.5 kg), but this is acceptable given the life-threatening nature of anaphylaxis 1

Common fatal anaphylaxis associations: Adolescence, concomitant poorly-controlled asthma, and failure to inject epinephrine promptly 1.